Author(s):
Robert A Byrne
Added:
1 year ago
ESC 2023 — Dr Robert Byrne (Mater Private Hospital, Dublin, IE) joins us on-site to discuss the new guidelines from the ESC covering the management of acute coronary syndromes.
Acute Coronary Syndrome (ACS) is a broad spectrum of conditions, and the presentation can vary from a stable patient, to a patient who is critically ill. In the past, separate guidelines were issued for ST-Elevation…
View more
Author(s):
Harriette Van Spall,Kausik Ray
Added:
5 months ago
AHA Conference 2024 — Key findings from the ZODIAC trial investigating the role of a decision support system in optimising lipid-lowering therapy for ACS patients.Dr Harriette Van Spall (McMaster University, CA) sits down with Prof Kausik Ray (Imperial College London, UK) to discuss the findings from the randomized controlled ZODIAC trial assessing decision support systems (DSS) in optimising…
View more
Job title: Professor Nicolau’s main area of research includes the broad spectrum of coronary artery disease (mainly ACS)
Prof José C Nicolau, Director of the Clinical Unit of Acute Coronary Disease of the Heart Institute - InCor / HCFMUSP, University of São Paolo, Brazil
Professor Nicolau’s main area of research includes the broad spectrum of coronary artery disease (mainly ACS), including hyperglycemia, LV remodeling, platelet reactivity, and antithrombotic therapy. He has participated in more than 80…
View more
Job title: Professor of Cardiology
Derek Chew is a clinical and interventional cardiologist as well as a clinical trialist, and health systems researcher in cardiovascular medicine. He has completed a Masters of Public Health at the Harvard School of Public Health, with formal training in epidemiology, trial design, biostatistics, clinical trials and cost-effectiveness analysis. His PhD thesis explored the factors for improving…
View more
Author(s):
Masahiro Natsuaki
Added:
1 year ago
ESC 23 — Dr Masahiro Natsuaki (Saga University, JP) discusses the short and optimal duration of dual antiplatelet therapy-3 Study (STOPDAPT-3) (NCT04609111).
In the STOPDAPT-2 study, 1-month dual antiplatelet therapy (DAPT) followed by clopidogrel monotherapy was shown to provide benefits in bleeding reduction over a 12-month period, however, other trials have shown high rates of bleeding at…
View more